Safety of High-Dose Melphalan (200 Mg/M2) as Conditioning for Autologous Stem Cell Transplantation for Myeloma in Elderly Patients
Amrita Desai(Oregon Health & Science University), Krishna V. Komanduri(University of Miami), Erik L. Kimble(University of Washington), Jeremy Ramdial(The University of Texas MD Anderson Cancer Center), Denise Pereira(Neurology Center of Southern California), Amer Beitinjaneh(University of Miami), Gabriela Bravo(University of Miami), Seyyedeh Saneeymehri(University of Miami), Vaia Florou(University of Utah), Mark Goodman(University of Miami), John Byrnes(SRI International), Lazaros J. Lekakis(University of Miami Hospital), Robert Ali(University of Virginia), Antonio Jiménez(University of Miami)
Cited by 4
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2020|1.9k
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
|Journal of Clinical Oncology|2020|782